Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

FDA panel voted favorably that there is reasonable assurance Shield is safe, effective, and outweigh its risks. The FDA is expected to decide whether to approve Shield later this year. Get ahead of ...

Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer Longitudinal circulating tumor DNA (ctDNA) ...

Barcelona-based testing service will advance cancer research and enable clinicians to personalize treatments more accurately and quickly for patients with late-stage cancer PALO ALTO, Calif. & ...

Blood test for minimal residual disease (MRD) now covered to monitor for disease recurrence after curative intent treatment Tissue-free approach addresses need for cancer patients who have no tissue ...

Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer ...

For the first time, fundamental tumor phenotypes determined by a simple blood test Single test now provides molecular tumor typing, subtyping and confirmation of absence of actionable biomarkers to ...

A looming revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster biotech stocks like Guardant Health, Natera and Exact Sciences. And all it takes is a little blood.

The Guardant Health Shield test, one committee member said, “is better than nothing for patients who are getting nothing, but it is not better than a colonoscopy.” By Gina Kolata A committee of ...